Associate Professor Kevin Broady obtained his PhD from the University of New South Wales in 1975 and worked at that university for the next three years as a Research Scientist studying the microbiology of dental caries, before taking up an Alexander von Humboldt Fellowship to work at the Max-Planck Institute of Immunobiology in Freiburg, Germany, describing the immunochemistry of Vibrio cholera LPS. Upon returning to Australia, he worked in the private pathology industry for several years, before returning to biomedical research at the Kolling Institute of Medical Research at Royal North Shore Hospital, in Sydney, Australia. One year later he was appointed to an academic position at the University of Technology, Sydney. His association has continued with Royal North Shore Hospital with membership of several committees including being Chair of the Joint RNSH/UTS Committee of Animal Care and Ethics Committee.

He was promoted to Associate Professor in 1984 and served as the first Head of the Department of Cell and Molecular Biology from1995-1999; Coordinator of Biotechnology Courses from 2000-2003; and then Chair of the Honours Committee from 2003-2005. In 2006 the Departments of Cell and Molecular Biology and Health Sciences amalgamated, with A/Professor Broady serving as the Head of the new Department of Medical and Molecular Biosciences from 2006-2009.

A/Professor Broady played a significant role in establishing research at UTS with the creation of the Immunobiology Unit with Professor Raison in 1990. He was also on the steering committee to establish the Institute for the Biotechnology of Infectious Diseases [IBID] in 2001 and has been a member of the Executive Committee of IBID [2002-2009].

Since his appointment to UTS his research interests have included the immunochemistry of toxins from Australian animals including ticks, snakes, spiders and scorpions. His especial research interest has been the Australian paralysis tick Ixodes holocyclus. A/Professor Broady has been instrumental in isolating the paralysing neurotoxin and determining the immunochemistry of the tick allergens. Research into snake venoms resulted in the establishment of an R&D syndicate, investigating inhibitors of PLA2 enzymes for the control and treatment of inflammatory diseases. His other research interests include the development of vaccines for fish parasitic diseases for the aquaculture industry, development of venom components as drugs and the use of monoclonal antibodies for cancer treatment. Each of these research areas has utilised his expertise in protein purification, characterisation and expression and production of recombinant proteins.

He is the author of over 30 publications in international, peer-reviewed scientific journals.